ARCA Cy5 EGFP mRNA (5-moUTP) Workflow
2026-09-10
ARCA Cy5 EGFP mRNA (5-moUTP) separates cellular uptake from productive translation through paired Cy5 and EGFP readouts. This practical workflow helps optimize mRNA transfection in mammalian cells, compare delivery systems, and troubleshoot localization, stability, and innate-response confounders.
Sodium Ascorbate: Cancer Assay Workflow
2026-09-10
Build reproducible redox and tumor-cell assays with Sodium Ascorbate, from fresh DMSO stock preparation through ROS, viability, and motility measurements. The workflow also shows how to use this mineral salt of ascorbic acid alongside—not as a substitute for—biomarker studies in immuno-oncology.
WEHI-539: A Translational Map of BCL-XL Dependence
2026-09-09
A thought-leadership guide to using WEHI-539 as a mechanistically precise BCL-XL inhibitor for mapping apoptotic dependence, interpreting cancer stem cell phenotypes, and strengthening translational study design.
Estradiol and the ER–Autophagy Axis in Aging
2026-09-09
A recent study integrates NHANES data, a perimenopausal mouse model, network pharmacology, and inhibitor-based validation to examine how declining estradiol affects the heart, aorta, and kidneys. Its findings connect estrogen receptor signaling with mTOR-related autophagy and tissue protection, while also showing why the results remain a mechanistic basis for further translational research rather than a clinical treatment recommendation.
Dovitinib in Hypoxia-Aware Cancer Research
2026-09-08
Dovitinib (TKI-258) enables mechanism-focused studies of RTK signaling, apoptosis, and tumor adaptation under hypoxic stress. This workflow connects quantitative pathway inhibition with assay designs relevant to multiple myeloma research and hepatocellular carcinoma treatment research.
Methoxy-X04 for Mechanism-Resolved Aβ Imaging
2026-09-08
Methoxy-X04 is a fluorescent amyloid beta probe for distinguishing aggregate-associated pathology from broader treatment effects in Alzheimer’s disease research. This guide develops a mechanism-focused imaging strategy for connecting rTMS, microglial clearance, plaque burden, and cerebrovascular amyloid visualization.
SB525334 in TGF-beta1 Receptor Studies
2026-09-07
SB525334 provides a selective way to test when ALK5 signaling drives fibrosis and when it supports repair, angiogenesis, or immune coordination. This workflow translates bone-transport diabetic wound findings into practical cellular, tissue, and renal fibrosis model experiments without treating pathway inhibition as inherently beneficial.
Directional Migration, Surface Signals, and TSA
2026-09-05
A thought-leadership guide connecting the Upd2–JAK/STAT control of directional tracheal stem-cell migration with membrane-impermeant tyramide chemistry for selective cell-surface profiling and translational assay design.
CDK4/6–BET Inhibition Rewires Wnt Signaling in PDAC
2026-09-05
Gu et al. show that palbociclib can restrain pancreatic ductal adenocarcinoma proliferation while paradoxically enhancing migration, invasion, and epithelial-to-mesenchymal transition. Combining CDK4/6 inhibition with the BET inhibitor JQ1 produced synergistic antitumor activity by counteracting GSK3β-mediated Wnt/β-catenin activation and disrupting its crosstalk with TGF-β/Smad signaling.
Phosphatase Inhibitor Cocktail: Protocol & QC
2026-09-04
Phosphatase Inhibitor Cocktail (2 Tubes, 100X), SKU K1015, is used during sample preparation to limit endogenous dephosphorylation across serine/threonine and tyrosine phosphatase activities. It supports research workflows such as immunoblotting, immunoprecipitation, kinase assays, and mass spectrometry, but requires matrix-specific validation and is not intended for diagnostic or medical use.
Etoposide (VP-16): DNA Damage Research Guide
2026-09-04
Etoposide (VP-16) is a DNA topoisomerase II poison that converts transient enzyme–DNA cleavage complexes into persistent DNA damage. Its reported activity varies substantially by assay and cell line, making model-specific controls, DMSO handling, and endpoint selection essential for reproducible cancer research.
ERAD-Hijacking for Transmembrane Protein Degradation
2026-09-03
Song et al. establish ERAD-engaging chimeras (ERADECs), a targeted protein degradation platform that redirects the endoplasmic reticulum-associated degradation pathway toward transmembrane proteins. Desonide-based ERADECs efficiently degraded PD-L1 and mutant huntingtin through the ER E3 ligase SYVN1, highlighting a small-molecule route that complements lysosome-dependent degradation technologies.
Cytarabine Beyond DNA Synthesis: A Translational Map
2026-09-03
Cytarabine and AraC are more than viability reagents. This thought-leadership guide connects deoxycytidine kinase activation, DNA damage, p53-mediated apoptosis, and RIPK3-centered cell-death phenotyping to improve leukemia research design and translational decision-making.
qPCR Quantification of Moloney Murine Leukemia Virus
2026-09-02
Choi, Murphy, and Nitta developed a real-time PCR assay that targets the packaging signal–gag region of Moloney murine leukemia virus (M-MuLV) and distinguishes exogenous viral sequences from related endogenous retroviruses in mouse cells. The assay quantified cell-associated viral sequences across post-infection samples and provided a faster, scalable complement to focal immunofluorescence assays, while retaining important limitations in interpreting infectivity.
Oxaliplatin: DNA Damage and CRC Research
2026-09-02
Oxaliplatin is a platinum-based chemotherapeutic agent that creates DNA adducts and supports apoptosis induction via DNA damage. Its established role in metastatic colorectal cancer therapy also makes it useful for cancer chemotherapy, DNA repair, and resistance research.
466 records 6/32 page Previous Next First page 上5页 678910 下5页 Last page